20 June 2023: Original Paper
Survival Analysis of Transplant-Associated Thrombotic Microangiopathy Under Different Diagnostic Criteria and Efficacy of Plasma Exchange
Yifan Xu 12ABCDEF , Yan Wei 12BF , Lijun Wang 2BC , Ning Lu 2BD , Yongli Wu 2BD , Liping Dou 2AF , Daihong Liu 2AF , Meng Li 2ADEF* , Chunji Gao 2ADEFG*DOI: 10.12659/AOT.939890
Ann Transplant 2023; 28:e939890
Table 1 Clinical characteristics of the TA-TMA.
| Characteristics | Total subjects (n=32) | PE (n=21) | Non-PE (n=11) | P value |
|---|---|---|---|---|
| 33.5 (13–61) | 34 (13–61) | 30 (15–61) | 0.690 | |
| 0.703 | ||||
| Male | 22 (68.8%) | 15 (71.4%) | 7 (63.6%) | |
| Female | 10 (31.2%) | 6 (28.6%) | 4 (36.4%) | |
| >0.99 | ||||
| AA | 2 (6.2%) | 1 (4.8%) | 1 (9.1%) | |
| MDS/AML/CML | 18 (56.3%) | 12 (57.1%) | 6 (54.5%) | |
| ALL | 12 (37.5%) | 8 (38.1%) | 4 (36.4%) | |
| >0.99 | ||||
| BU/CY+ATG | 29 (90.6%) | 19 (90.5%) | 10 (90.9%) | |
| FluCY-ATG | 1 (3.1%) | 1 (4.8%) | 0 (0.0%) | |
| TBI/CY/ATG | 2 (6.3%) | 1 (4.8%) | 1 (9.1%) | |
| 0.269 | ||||
| MUD | 4 (12.5%) | 4 (19.0%) | 0 (0.0%) | |
| Haplo | 26 (81.3%) | 15 (71.4%) | 11 (100.0%) | |
| MRD | 2 (6.2%) | 2 (9.5%) | 0 (0.0%) | |
| 0.283 | ||||
| Yes | 19 (59.4%) | 14 (66.7%) | 5 (45.5%) | |
| No | 13 (40.6%) | 7 (33.3%) | 6 (54.5%) | |
| >0.99 | ||||
| ABO mismatch | 9 (28.1%) | 6 (28.6%) | 3 (27.3%) | |
| ABO matched | 23 (71.9%) | 15 (71.4%) | 8 (72.7%) | |
| 0.071 | ||||
| HLA matched | 6 (18.8%) | 6 (28.6%) | 0 (0.0%) | |
| HLA mismatch | 26 (81.3%) | 15 (71.4%) | 11 (100.0%) | |
| 66.5 (22–591) | 91.0 (22–591) | 39.0 (29–234) | 0.005 | |
| TBIL (μmol/L), median | 12.9 (4.7–329.0) | 16.1 (4.7–329.0) | 11.3 (6.8–67.6) | 0.427 |
| PLT (×10/L), median | 22 (3–165) | 18 (3–165) | 28 (13–74) | 0.627 |
| Hb (g/L) | 69.7±13.2 | 66.7±13.4 | 75.4±11.4 | 0.013 |
| Schistocytes (%), median | 1.0 (0.0–4.0) | 1.5 (0.0–4.0) | 1.0 (0.0–1.2) | 0.157 |
| LDH (U/L), median | 355.0 (196.6–1790.4) | 380.0 (196.6–1790.4) | 336.2 (273.8–469.0) | 0.565 |
| 0.465 | ||||
| Yes | 12 (37.5%) | 9 (42.9%) | 3 (27.3%) | |
| No | 20 (62.5%) | 12 (57.1%) | 8 (72.7%) | |
| 0.072 | ||||
| Yes | 19 (59.4%) | 15 (71.4%) | 4 (36.3%) | |
| No | 13 (40.6%) | 6 (28.6%) | 7 (63.6%) | |
| 0.458 | ||||
| Yes | 21 (65.5%) | 12 (75.0%) | 9 (56.3%) | |
| No | 11 (34.4%) | 4 (25.0%) | 7 (43.8%) | |
| 0.465 | ||||
| Yes | 12 (37.5%) | 9 (42.9%) | 3 (27.3%) | |
| No | 20 (62.5%) | 12 (57.1%) | 8 (72.7%) | |
| 0.465 | ||||
| Yes | 14 (43.8%) | 8 (38.1%) | 6 (54.5%) | |
| No | 18 (56.3%) | 13 (61.9%) | 5 (45.5%) | |
| 0.123 | ||||
| Yes | 21 (65.6%) | 16 (76.2%) | 5 (45.5%) | |
| No | 11 (34.4%) | 5 (23.8%) | 6 (54.5%) | |
| >0.99 | ||||
| Yes | 31 (96.9%) | 20 (95.2%) | 1 1(100.0%) | |
| No | 1 (3.1%) | 1 (4.8%) | 0 (0.0%) | |
| Data are presented as the mean±SD, range (minimum-maximum), or n (%). HLA – human leukocyte antigen; AML – acute myeloblastic leukemia; ALL – acute lymphoblastic leukemia; CML – chronic myelogenous leukemia; MDS – myelodysplastic syndrome; AA – aplastic anemia; BU – busulfan; CY – cyclophosphamide; ATG – anti-thymocyte globulin; Flu – fludarabine; Haplo – haploidentical; MRD – matched related donor; MUD – matched unrelated donor. | ||||